Industry MedicalSpecialties
For the last three days, A.I.dvisor has detected that WGS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for WGS, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 232 similar cases, of which were successful. Based on this data, the odds of success are
The Aroon Indicator for WGS entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator formed such a pattern. In 217 of the 232 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WGS as a result. In 66 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for WGS turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where WGS's RSI Indicator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where WGS advanced for three days, in 233 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
WGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.616) is normal, around the industry mean (67.298). P/E Ratio (-17.182) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.270) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. WGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
GeneDx Holdings Corp. shares closed at $62.37 on November 6, 2026, down 3.09% for the session and roughly 7% below levels seen 30 days prior. The pullback follows a much larger retreat from the stock's 52-week high of $170.87, underscoring how quickly sentiment has shifted for a high-growth, high-volatility genomics name. With a market capitalization near $1.9 billion and a beta above 1.9, WGS remains one of the more volatile mid-cap holdings in the healthcare diagnostics sector.
The broader backdrop has been one of profit-taking and re-rating. After rising sharply earlier in 2026, GeneDx shares have consolidated lower as investors weigh rapid top-line growth against persistent questions about cash generation and the pace of reimbursement collections. The stock still trades above its 52-week low of $32.21, and the consensus analyst view remains constructive, but near-term momentum has clearly weakened.
GeneDx Holdings Corp. is a genomics company focused on exome and whole-genome sequencing to diagnose rare and ultra-rare genetic pediatric disorders. Its core offerings, ExomeDx and GenomeDx, are supported by the proprietary GeneDx Infinity dataset—built from more than 2.5 million tests, including over one million exomes and genomes—and by AI-powered interpretation pipelines designed to deliver faster, more accurate diagnoses. The company also provides biopharma data services and genomic newborn screening.
Headquartered in Stamford, Connecticut, GeneDx positions itself as a pioneer in moving exome and genome testing toward becoming the standard of care for genetic disease. Investors follow the stock for its exposure to precision medicine, its large and growing proprietary dataset, and its expanding routes to market—including a primary-care initiative, rapid NICU and PICU testing, and a newly launched prenatal whole-genome sequencing product, GenomeDx Prenatal. Competitive strengths include its scale of interpreted genomic data, clinical expertise, and a first-mover position in the rare-disease diagnostics market.
Several verified developments have shaped the WGS narrative in recent weeks. The company announced plans to enhance its genome testing portfolio with long-read whole-genome sequencing (lrWGS), which analyzes longer stretches of DNA to identify complex variants that shorter-read methods may miss. This expansion reinforces GeneDx's diagnostic leadership and its effort to differentiate its portfolio.
GeneDx also launched sponsored testing programs in collaboration with Mirum Pharmaceuticals (MIRM), offering no-cost exome testing for eligible patients across three areas: cholestasis, early-onset cataracts, and peroxisomal disorders. Such partnerships broaden patient access while diversifying GeneDx's revenue channels.
Meanwhile, reimbursement dynamics remain a recurring source of volatility. Management has indicated that only a minority of genome claims were being collected as expected, with many denials administrative in nature, and that meaningful improvement was not anticipated until late 2026 or 2027. The company also cut its 2026 revenue outlook earlier in the year amid lower blended reimbursement and weaker non-core activity, before reaffirming guidance of $475 million to $490 million alongside its second-quarter results. Third-quarter results were scheduled for November 9, 2026, making earnings a focal point for investors.
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that currently rank among the platform's top-performing and most relevant strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only a focused group of the strongest and most timely bots appears in this section. The featured bots vary by trading strategy, timeframe, and performance metrics, giving traders a range of approaches to evaluate. For those seeking data-driven perspectives on active names such as GeneDx Holdings, the Trending AI Robots page offers a practical starting point to explore automated trading ideas.
Looking ahead, the most important drivers for WGS center on execution and reimbursement. Investors are likely to monitor whether GeneDx sustains double-digit exome and genome test-volume growth while improving cash collection rates, a factor management has flagged as improving only gradually through late 2026 and into 2027. Progress on commercial and Medicaid coverage expansion—including the share of states covering exome or genome testing—will be closely watched.
Product catalysts such as the GenomeDx Prenatal launch and long-read whole-genome sequencing could widen GeneDx's addressable market, while new partnerships and sponsored testing programs may support volumes. At the same time, risks include uneven medical-policy decisions, test-mix shifts that pressure blended reimbursement, and the company's reliance on near-term cost discipline and collections to strengthen its cash position. The consensus "Strong Buy" rating and average price target near $93.50 reflect optimism, but the gap between that target and the current share price highlights both the upside potential and the uncertainty that continues to surround this high-beta genomics name.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.